These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21847900)

  • 21. Bias at the gate?: The pharmaceutical industry's influence on the federally approved drug compendia.
    Gabrielsen L
    Am J Law Med; 2014; 40(1):141-63. PubMed ID: 24844045
    [No Abstract]   [Full Text] [Related]  

  • 22. Commercial speech, drugs, promotion and a tailored advertisement moratorium.
    Gilhooley M
    Health Matrix Clevel; 2011; 21(1):97-109. PubMed ID: 21847898
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug and device litigation in the 21st century.
    Svitak LS; Goss PJ
    Spec Law Dig Health Care Law; 2001 Nov; (271):9-36. PubMed ID: 11802352
    [No Abstract]   [Full Text] [Related]  

  • 24. Off-label marketing: free speech or illegal promotion?
    Silverman E
    BMJ; 2013 Jan; 346():f320. PubMed ID: 23341546
    [No Abstract]   [Full Text] [Related]  

  • 25. Regulating off-label promotion of medications: has the pendulum swung too far?
    Hoffman MB; Yentzer BA; Feldman SR
    Skin Therapy Lett; 2015; 20(3):1-4. PubMed ID: 26382556
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Court rules that FDA cannot restrict off-label marketing.
    Roehr B
    BMJ; 2015 Aug; 351():h4367. PubMed ID: 26265632
    [No Abstract]   [Full Text] [Related]  

  • 27. The strange allure of state "right-to-try" laws.
    Zettler PJ; Greely HT
    JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical trial transparency--antidote to weaker off-label-promotion rules?
    Outterson K
    N Engl J Med; 2014 Jul; 371(1):1-3. PubMed ID: 24988551
    [No Abstract]   [Full Text] [Related]  

  • 29. The Promotion of Medical Products in the 21st Century: Off-label Marketing and First Amendment Concerns.
    Sharfstein JM; Charo A
    JAMA; 2015 Nov; 314(17):1795-6. PubMed ID: 26367520
    [No Abstract]   [Full Text] [Related]  

  • 30. Certification denied in pharmaceutical class action.
    Boudreau A; Tombs A
    Health Law Can; 2012 Aug; 33(1):1-4. PubMed ID: 23097924
    [No Abstract]   [Full Text] [Related]  

  • 31. Pharmaceuticals and medical devices: FDA oversight. End-of-year issue brief.
    Chaps NA
    Issue Brief Health Policy Track Serv; 2008 Jan; ():1-18. PubMed ID: 18345557
    [No Abstract]   [Full Text] [Related]  

  • 32. Origins of the prohibition against off-label promotion.
    Coleman TS
    Food Drug Law J; 2014; 69(2):161-236, i. PubMed ID: 25163210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pfizer settles largest ever fraud suit for off-label promotion.
    Ratner M
    Nat Biotechnol; 2009 Nov; 27(11):961-2. PubMed ID: 19898429
    [No Abstract]   [Full Text] [Related]  

  • 34. Understanding government regulation of the marketing and advertising of medical devices, drugs, and biologics: the challenges of the Internet.
    Reichertz PS
    Food Drug Law J; 1997; 52(3):303-8. PubMed ID: 10343029
    [No Abstract]   [Full Text] [Related]  

  • 35. Restrictions on pharmaceutical detailing reduced off-label prescribing of antidepressants and antipsychotics in children.
    Larkin I; Ang D; Avorn J; Kesselheim AS
    Health Aff (Millwood); 2014 Jun; 33(6):1014-23. PubMed ID: 24889951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defining "True and Non-Misleading" for Pharmaceutical Promotion.
    Hey SP; Kesselheim AS
    J Law Med Ethics; 2018 Jun; 46(2):552-554. PubMed ID: 30146990
    [No Abstract]   [Full Text] [Related]  

  • 37. Pharmaceuticals and Medical Devices: Business Practices.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2015 Dec; ():1-37. PubMed ID: 27116796
    [No Abstract]   [Full Text] [Related]  

  • 38. Prohibition against off-label drug promotion challenged.
    Woodward C
    CMAJ; 2012 Mar; 184(5):518. PubMed ID: 22353585
    [No Abstract]   [Full Text] [Related]  

  • 39. Truth, Falsity, and Fraud: Off-Label Drug Settlements and the Future of the Civil False Claims Act.
    Krause JH
    Food Drug Law J; 2016; 71(3):401-40. PubMed ID: 29140064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug manufacturers' First Amendment right to advertise and promote their products for off-label use: avoiding a pyrrhic victory.
    Blackwell AE; Beck JM;
    Food Drug Law J; 2003; 58(3):439-62. PubMed ID: 14626985
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.